These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21892908)

  • 1. Increased plasma concentrations of tumour markers in the absence of neoplasia.
    Trapé J; Filella X; Alsina-Donadeu M; Juan-Pereira L; Bosch-Ferrer Á; Rigo-Bonnin R;
    Clin Chem Lab Med; 2011 Oct; 49(10):1605-20. PubMed ID: 21892908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS.
    Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M
    Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
    Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
    J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced ovarian cancer. Tumour markers.
    Rustin GJ; van der Burg ME; Berek JS
    Ann Oncol; 1993; 4 Suppl 4():71-7. PubMed ID: 8312203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of tumor markers in serum. Pitfalls and good practice.
    Basuyau JP; Leroy M; Brunelle P
    Clin Chem Lab Med; 2001 Dec; 39(12):1227-33. PubMed ID: 11798082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
    Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
    Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumour markers in patients with chronic kidney disease.
    Xiaofang Y; Yue Z; Xialian X; Zhibin Y
    Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Fiala O; Pesek M; Finek J; Svaton M; Sorejs O; Bortlicek Z; Kucera R; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):461-6. PubMed ID: 26722082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours.
    Lenhard M; Kuemper C; Ditsch N; Diebold J; Stieber P; Friese K; Burges A
    Clin Chem Lab Med; 2007; 45(5):657-61. PubMed ID: 17484630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.